Eli Lilly and Company (NYSE:LLY) Shares Sold Rep. Michael A. Rulli

Representative Michael A. Rulli (Republican-Ohio) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on August 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on July 1st. The trade occurred in the Representative’s “MERRILL LYNCH MANAGED ACCOUNT” account.

Representative Michael A. Rulli also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Crown Castle (NYSE:CCI) on 8/6/2026.
• Purchased $1,001 – $15,000 in shares of KLA (NASDAQ:KLAC) on 7/1/2026.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 6/29/2026.
• Purchased $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 6/25/2026.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 6/25/2026.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 6/25/2026.
• Purchased $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 6/25/2026.
• Sold $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 6/25/2026.
• Sold $1,001 – $15,000 in shares of Apple (NASDAQ:AAPL) on 6/25/2026.

Eli Lilly and Company Stock Down 0.8%

Shares of LLY traded down $9.67 during mid-day trading on Tuesday, hitting $1,222.27. 440,409 shares of the company’s stock were exchanged, compared to its average volume of 3,124,779. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. Eli Lilly and Company has a 52 week low of $629.40 and a 52 week high of $1,249.45. The company has a market cap of $1.15 trillion, a PE ratio of 41.05, a P/E/G ratio of 1.38 and a beta of 0.51. The company has a 50-day simple moving average of $1,162.38 and a 200 day simple moving average of $1,048.95.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.Eli Lilly and Company’s revenue was up 47.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, research analysts forecast that Eli Lilly and Company will post 36.77 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is 23.22%.

Hedge Funds Weigh In On Eli Lilly and Company

Hedge funds have recently bought and sold shares of the business. Osbon Capital Management LLC acquired a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $25,000. Basso Capital Management L.P. acquired a new stake in shares of Eli Lilly and Company during the fourth quarter valued at about $30,000. Maseco LLP grew its holdings in shares of Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after purchasing an additional 28 shares during the last quarter. E Fund Management Hong Kong Co. Ltd. increased its stake in shares of Eli Lilly and Company by 342.9% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after buying an additional 24 shares during the period. Finally, Aventus Investment Advisors Inc. raised its holdings in Eli Lilly and Company by 270.0% in the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock valued at $34,000 after buying an additional 27 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.K. Medicines and Healthcare products Regulatory Agency approved Foundayo for weight loss and weight maintenance in certain adults with obesity or overweight-related conditions. The decision marks the pill’s first approval outside the United States and opens access to a large European market. It will initially be available through private prescriptions, while potential National Health Service coverage awaits a cost-effectiveness review. Eli Lilly takes weight-loss pill battle global
• Positive Sentiment: Foundayo’s approval strengthens Lilly’s competitive position against Novo Nordisk in the fast-growing obesity-treatment market. Investors see an effective oral option as potentially expanding GLP-1 adoption beyond injectable therapies and supporting future revenue growth. Why Eli Lilly Topped the Market Today
• Positive Sentiment: Lilly’s latest quarterly results continue to underpin investor confidence. Second-quarter revenue increased 47.7% year over year to approximately $23.0 billion, and EPS of $8.38 exceeded the $6.40 consensus estimate. Fiscal 2026 EPS guidance is $35.50 to $36.50, reflecting sustained demand for Mounjaro, Zepbound and other growth products. Eli Lilly Posts Blowout Growth and Raises Its Outlook
• Positive Sentiment: An updated valuation analysis raised Lilly’s fair-value estimate from $1,270.37 to $1,297.31, citing the company’s GLP-1 portfolio, recent earnings performance and pipeline opportunities including retatrutide and Foundayo. Eli Lilly Stock Gets Fair Value Bump
• Neutral Sentiment: Analyst H. Engel of Erste Group Bank reduced the firm’s 2026 EPS estimate to $34.93 from $35.34, below the broader consensus estimate of $36.77. The modest revision may temper enthusiasm, although it remains small relative to Lilly’s strong operating momentum.
• Negative Sentiment: Executive Vice President Anat Hakim sold 5,000 shares for approximately $5.95 million. Because the transaction was executed under a pre-arranged Rule 10b5-1 plan, it is a limited signal regarding management’s view of Lilly’s future prospects. SEC Form 4 Filing

Analyst Upgrades and Downgrades

Several research firms recently weighed in on LLY. Guggenheim raised their target price on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a research note on Monday, July 13th. BMO Capital Markets reissued an “outperform” rating and issued a $1,400.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 6th. The Goldman Sachs Group reiterated a “buy” rating and issued a $1,283.00 target price on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Bank of America boosted their price target on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Finally, Berenberg Bank lifted their target price on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a “hold” rating in a research note on Monday, June 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $1,292.18.

Insider Buying and Selling

In other news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by corporate insiders.

About Representative Rulli

Michael Rulli (Republican Party) is a member of the U.S. House, representing Ohio’s 6th Congressional District. He assumed office on June 25, 2024. His current term ends on January 3, 2027.

Rulli (Republican Party) is running for re-election to the U.S. House to represent Ohio’s 6th Congressional District. He declared candidacy for the 2026 election.

Michael Rulli graduated from Poland Seminary High School. He earned a degree from Emerson College. Rulli’s career experience includes working as the director of operations with Rulli Bros. Markets.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.